Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.54 |
| ▸ | DPP4 | P27487 | 1/20 | 0.53 |
| ▸ | POLA1 | P09884 | 1/20 | 0.47 |
| ▸ | NEK2 | P51955 | 1/20 | 0.46 |
| ▸ | BRAF | P15056 | 1/20 | 0.43 |
| ▸ | XDH | P47989 | 1/20 | 0.42 |
| ▸ | STAT3 | P40763 | 4/20 | 0.41 |
| ▸ | SRC | P12931 | 2/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | MGMT | P16455 | 1/20 | 0.39 |
| ▸ | CDC7 | O00311 | 1/20 | 0.38 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4307867 | 0.84 | DPP4 (0.49) | GDADPP4POLA1NEK2XDH | |
| SCHEMBL887125 | 0.83 | GDA (0.55) | GDANEK2BRAFSTAT3SRC | |
| SCHEMBL31506448 | 0.83 | GDA (0.55) | GDANEK2BRAFXDHSTAT3 | |
| SCHEMBL750335 | 0.83 | GDA (0.55) | GDANEK2BRAFXDHSTAT3 | |
| SCHEMBL9412610 | 0.82 | DPP4 (0.50) | GDADPP4POLA1NEK2XDH | |
| SCHEMBL9412467 | 0.82 | DPP4 (0.50) | GDADPP4POLA1NEK2XDH | |
| SCHEMBL14938904 | 0.82 | GDA (0.54) | GDADPP4POLA1NEK2BRAF | |
| SCHEMBL15063958 | 0.81 | SYK (0.52) | GDADPP4POLA1XDHSTAT3 | |
| Acetic Acid SCHEMBL7594624 | 0.80 | DPP4 (0.48) | GDADPP4POLA1NEK2XDH | |
| SCHEMBL5197095 | 0.77 | CYP1A2 (0.39) | GDABRAFCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0644193-B1 | Process for preparing 2-acetylamino-6-chloropurine | JUZEN CHEMICAL CO LTD (JP) | 2000-04-26 | — | — | EP | claimed |
| US-5688778-A | VIRICIDES | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 1997-11-18 | — | — | US | claimed |
| EP-0684243-A1 | Process for preparing 2-amino-6-chloropurine and 2-acylamino-6-chloropurine | BOEHRINGER INGELHEIM KG (DE) | 1995-11-29 | — | — | EP | claimed |
| EP-0644193-A2 | Process for preparing 2-acetylamino-6-chloropurine | JUZEN CHEMICAL CO.LTD. (JP) | 1995-03-22 | — | — | EP | claimed |
| JP-7133276-A | — | — | None | — | — | JP | disclosed |
| CN-113234077-B | Synthesis method of 2-amino-6-chloropurine | 上海凌凯医药科技有限公司 | 2022-03-08 | — | — | CN | disclosed |
| CN-113234077-A | Synthesis method of 2-amino-6-chloroguanine | 上海凌凯医药科技有限公司 | 2021-08-10 | — | — | CN | disclosed |
| WO-2012115578-A1 | SYNTHESIS OF FLG | MEDIVIR AB (SE) | 2012-08-30 | — | — | WO | disclosed |
| EP-1816135-A1 | Production method of fluorinated purine nucleoside derivative, intermediate therefor and production method thereof | Ajinomoto Co., Inc. (JP) | 2007-08-08 | — | — | EP | disclosed |
| US-20050171126-A1 | Process for the production of purine nucleoside compounds | AJINOMOTO CO., INC. (JP) | 2005-08-04 | — | — | US | disclosed |
| EP-1550665-A1 | A process for the production of purine nucleoside compounds | Ajinomoto Co., Inc. (JP) | 2005-07-06 | — | — | EP | disclosed |
| CN-1206226-C | Method for preparing effective anti-virus cyclopropane derivative and intermediate used thereof | AJINOMOTO KK (JP) | 2005-06-15 | — | — | CN | disclosed |
| EP-0464511-A2 | Process for the preparation of acyclic, substituted nucleosides and its intermediates | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-01-08 | — | — | EP | disclosed |
| CN-1057652-A | A kind of acyclic nucleotide of replacement and method of related intermediates thereof of preparing | HOECHST AG (DE) | 1992-01-08 | — | — | CN | disclosed |
| EP-0452680-A1 | Substituted purines, process for their preparation and their use as antiviral agents | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-10-23 | — | — | EP | disclosed |
| EP-0433846-A1 | Process for the preparation of 2-acylamino-6-halogeno-purine from 2,9-diacylguanine | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-06-26 | — | — | EP | disclosed |
| EP-0433845-A1 | Process for the preparation of 2-acylamino-9-acyl-6-halogeno-purines | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-06-26 | — | — | EP | disclosed |
| EP-0302644-A2 | Purine compounds and their preparation | BEECHAM GROUP PLC (GB) | 1989-02-08 | — | — | EP | disclosed |
| US-4801710-A | Regioselective synthesis of 9-substituted purine acyclonucleoside derivatives | MERCK & CO., INC. (US) | 1989-01-31 | — | — | US | disclosed |
| EP-0184473-A1 | Regioselective synthesis of 9-substituted purine acyclonucleoside derivatives | MERCK & CO. INC. (US) | 1986-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171126-A1 | Process for the production of purine nucleoside compounds | PNP, NUDT1, UMPS | GDA 66/4885DPP4 314/4885POLA1 576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.